Clinical trial

ENDOCARE-SCREEN: Metabolic Liver Dysfunction Screening Study

Opening soon · Not applicable · 1 countries · Registry ID NCT07336563

Opening soonNot applicableObservational

What this study is about

The ENDOCARE-SCREEN study is a single-center, observational, cross-sectional screening study designed to assess the prevalence, phenotypes, and determinants of metabolic dysfunction-associated steatotic liver disease (MASLD/MAFLD) in adults with components of metabolic syndrome. Up to 10,000 participants aged ≥18 years with overweight, obesity, or metabolic risk factors will undergo standardized screening including a health questionnaire, anthropometric measurements, blood pressure assessment, laboratory testing, and liver ultrasound. The study aims to generate a comprehensive metabolic-hepatic dataset integrating clinical, laboratory, imaging, and lifestyle data. Collected data will be used to identify metabolic and behavioral risk factors for MASLD, characterize disease phenotypes, and support the development of predictive models. The ENDOCARE-SCREEN study will also serve as a qualification platform for selecting eligible participants for a subsequent interventional randomized controlled trial (ENDOCARE-SUPPORT). The study involves minimal risk procedures routinely used in clinical practice and follows ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice (GCP) guidelines.

A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.

Basic eligibility

Age18 Years to 75 Years

SexAll

Healthy volunteersNot accepted

ConditionMetabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH), Metabolic Syndrome, Obesity & Overweight, Obesity Type 2 Diabetes Mellitus, Insulin Resistance Syndrome

Full registry criteria

Inclusion Criteria: * Age 18-75 years. * Overweight or obesity (BMI ≥ 25 kg/m²) and/or increased waist circumference and/or at least one metabolic risk factor (e.g., hypertension, dyslipidemia, impaired fasting glucose/prediabetes/type 2 diabetes), as applicable per screening program. * Participation in the ENDOCARE screening program. * Ability to provide written informed consent, including consent for processing health-related data Exclusion Criteria: * Inability to provide informed consent (e.g., significant cognitive impairment, acute severe psychiatric disorder, language barrier). * Pregnancy or breastfeeding. * Known advanced liver diseases at baseline (participants may be excluded from primary analyses and/or described separately, per statistical analysis plan). * Refusal of key screening procedures (e.g., blood sampling or liver ultrasound) preventing determination of liver status. * Refusal of data processing under General Data Protection Regulation (GDPR) requirements.

Treatments and study arms

The registry does not list a named intervention.

Primary outcomes

Prevalence of MAFLD/MASLDBaseline (single screening visit)

Proportion of participants meeting MAFLD/MASLD criteria according to current definitions

Distribution of hepatic steatosis severity on liver ultrasoundBaseline (single screening visit)

Ultrasound steatosis grade (0-3): mild (1), moderate (2), severe (3).

Study locations

1 locations were listed when this page was built. The first 40 are shown.

ENDOCARE🇵🇱 Wroclaw, Poland

Open map

Katarzyna Tejza, MScContact

Email · Call 71 726 67 00

Jarosław Drobnik, Prof. MD, PhDPrincipal Investigator